Cargando…

Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies

Currently, immune checkpoint inhibitors (ICIs) are widely considered the standard initial treatment for advanced non-small cell lung cancer (NSCLC) when there are no targetable driver oncogenic alternations. NSCLC tumors that have two alterations in tumor suppressor genes, such as liver kinase B1 (L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Ichidai, Koyama, Junji, Itoigawa, Hideyuki, Hayai, Shunsaku, Morise, Masahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477992/ https://www.ncbi.nlm.nih.gov/pubmed/37675220 http://dx.doi.org/10.3389/fonc.2023.1249237

Ejemplares similares

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer
por: Matsuzawa, Reiko, et al.
Publicado: (2021)

The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence
por: Tanaka, Ichidai, et al.
Publicado: (2021)

Is area under the curve the best parameter for carboplatin induced emetic risk stratification?
por: Ozone, Sachiko, et al.
Publicado: (2021)

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
por: Meyers, Daniel E., et al.
Publicado: (2017)

The KEAP1–NRF2 System in Cancer
por: Taguchi, Keiko, et al.
Publicado: (2017)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges
por: Perutelli, Francesca, et al.
Publicado: (2022)

CircKEAP1 Suppresses the Progression of Lung Adenocarcinoma via the miR-141-3p/KEAP1/NRF2 Axis
por: Wang, Yanbo, et al.
Publicado: (2021)

Targeting Versican as a Potential Immunotherapeutic Strategy in the Treatment of Cancer
por: Hirani, Priyanka, et al.
Publicado: (2021)

Kiss1 Inhibits the Proliferation of Nasopharyngeal Carcinoma Cells Via Activation of the LKB1/AMPK Pathway
por: Li, Tingting, et al.
Publicado: (2022)

Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
por: Huffman, Kenneth E., et al.
Publicado: (2023)

Immunotherapeutic Advancements for Glioblastoma
por: Ampie, Leonel, et al.
Publicado: (2015)

Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC
por: He, Ping, et al.
Publicado: (2023)

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
por: Patel, Shabnum, et al.
Publicado: (2019)

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
por: Mitsuishi, Yoichiro, et al.
Publicado: (2012)

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1
por: Moehler, Markus, et al.
Publicado: (2014)

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018)

Angustoline Inhibited Esophageal Tumors Through Regulating LKB1/AMPK/ELAVL1/LPACT2 Pathway and Phospholipid Remodeling
por: Li, Huiying, et al.
Publicado: (2020)

Association between LKB1 expression and prognosis of patients with solid tumours: an updated systematic review and meta-analysis
por: Ren, Yun Hong, et al.
Publicado: (2019)

Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors
por: Nakagawa, Natsuki, et al.
Publicado: (2022)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
por: Thorne, Steve H.
Publicado: (2014)

Experiences and Expectations for Glioma Immunotherapeutic Approaches
por: Yamanaka, Ryuya, et al.
Publicado: (2014)

Immunotherapeutic Potential of T Memory Stem Cells
por: Li, Yujie, et al.
Publicado: (2021)

PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway
por: Tuo, Lin, et al.
Publicado: (2018)

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion
por: Xu, Jiaqian, et al.
Publicado: (2020)

Keap1 mutations in lung cancer patients
por: SASAKI, HIDEFUMI, et al.
Publicado: (2013)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
por: Gen, Soei, et al.
Publicado: (2022)

Somatic LKB1 Mutations Promote Cervical Cancer Progression
por: Wingo, Shana N., et al.
Publicado: (2009)

Attenuated Bacteria as Immunotherapeutic Tools for Cancer Treatment
por: Kaimala, Suneesh, et al.
Publicado: (2018)

Activation of p62/SQSTM1–Keap1–Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer
por: Ichimura, Yoshinobu, et al.
Publicado: (2018)

LKB1 tumor suppressor: Therapeutic opportunities knock when LKB1 is inactivated
por: Zhou, Wei, et al.
Publicado: (2014)

Versatile Roles of LKB1 Kinase Signaling in Neural Development and Homeostasis
por: Kuwako, Ken-ichiro, et al.
Publicado: (2018)

BASP1 is a prognostic biomarker associated with immunotherapeutic response in head and neck squamous cell carcinoma
por: Pan, Xue, et al.
Publicado: (2023)

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
por: Borzi, Cristina, et al.
Publicado: (2020)

Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)

LKB1 suppression promotes cardiomyocyte regeneration via LKB1-AMPK-YAP axis
por: Qu, Shuang, et al.
Publicado: (2022)

Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors
por: Ortiz, Michael V., et al.
Publicado: (2019)

T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?
por: Zhou, Qi, et al.
Publicado: (2020)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q9ketjpaune6lrfkta746vtdcn